X4 Pharmaceuticals (NASDAQ:XFOR) Announces Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) posted its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03), Zacks reports.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR opened at $0.30 on Tuesday. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. The firm’s 50 day moving average is $0.45 and its two-hundred day moving average is $0.53. The firm has a market capitalization of $51.23 million, a P/E ratio of -3.28 and a beta of 0.39. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60.

Insider Buying and Selling

In other news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 202,663 shares of company stock valued at $91,198 in the last three months. 1.62% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A hedge fund recently raised its stake in X4 Pharmaceuticals stock. Bank of America Corp DE raised its position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 20.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 133,502 shares of the company’s stock after buying an additional 22,485 shares during the quarter. Bank of America Corp DE owned 0.08% of X4 Pharmaceuticals worth $98,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.